N/A N=6 Low-dose UVA1 Radiation in Cutaneous Lupus Patients
Cutaneous Lupus Erythematosus
Primary: Change in Cutaneous Lupus Disease Area and Severity Index (CLASI) Activity Score — -1 Units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=31 Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus
Cutaneous Lupus Erythematosus
Primary: Percentage of Subjects Who Correctly Answered a Knowledge Assessment Item Immediately Before and After an Educational Lecture — 52; 94; 19; 90 percentage of participants
Phase 1 N=7 Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
Cutaneous Lupus
Primary: Change in Percentage of UVB-induced Apoptotic Epidermal Cells — 20.06; 3.03; -17.03 percentage of epidermal cells
N/A N=5 Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)
Cutaneous Lupus Erythematosus (CLE)
Primary: Cutaneous Lupus Area and Severity Index (CLASI) — 21.4; 10.8; 8.6; 5.3 units on a scale
Phase 2 N=78 Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus
Cutaneous Lupus Erythematosus
Primary: Percent Change From Baseline in Cutaneous Erythematosus Disease Area and Severity Index - Activity (CLASI-A) Sub-Score at Week 12 — -37.05; -42.76 percent change
Phase 1 N=11 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects
Lupus Erythematosus, Cutaneous
Primary: Number of Participants With Emergent Chemistry Results by Potential Clinical Importance (PCI) Criteria — 0; 11; 0; 10 Participants
Phase 2 N=12 Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients
Discoid Lupus Erythematosus
Primary: Cutaneous LE Diseases Area and Severity Index (CLASI) Score Based on Extent of Symptoms
Phase 2 N=54 Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions
Lupus Erythematosus, Discoid · Lupus Erythematosus, Systemic
Primary: Decrease in the Total Combined Erythema and Scaling Score (Minimum of 0 and Maximum of 65) of All Treated Lesions. — 22.2; 27.8 percentage of subjects
Phase 2 N=264 Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus · Active Cutaneous Lupus Erythematosus
Primary: Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 — -12.7; -9.0; -13.0; -14.5 joints — p=0.037
Phase 2 N=64 A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
Primary: Mean Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Improvement Compared to Placebo. — -6.2; -6.5; -6.2; -5.7 Scores on a scale — p=0.845
Phase 2 N=10 Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus
Discoid Lupus Erythematosus
Primary: Mean Severity of Disease as Measured by the Investigator's Global Assessment — 1.4 score on a scale
Phase 2 N=102 A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Primary: Percentage of Participants With a Systemic Lupus Erythematosus Responder Index (SRI-4) Composite Response (CR) at Week 24 — 33.3; 61.7 Percentage of participants…
Early Phase 1 N=16 IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus
Cutaneous Lupus Erythematosus
Primary: Cutaneous Lupus Erythematosus Disease Area and Severity Index - Total Activity Score (CLASI - TAS) — 100; 94; 84; 94 Percent of Baseline
Phase 2 N=47 Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
Cutaneous Lupus Erythematosus
Primary: Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score From Baseline to Week 12 — -4.5; -8.7; -5.5 score on a scale — p=0.7500
Phase 2 N=25 A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: Number of Participants With Treatment-emergent Adverse Events Following Administration With DS-7011a in Participants With Systemic Lupus Erythematosus — 11; 4 Participants
Phase 2 N=183 Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus
Lupus Erythematosus, Systemic
Primary: Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 24 — 59.9; 39.2; 40.1 Percentage of participants — p=0.076
Phase 2 N=42 A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
Systemic Lupus Erythematosus
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in Part 1 Treatment Phase — 5; 7; 7; 8 Participants
Phase 2 N=36 A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations
Systemic Lupus Erythematosus
Primary: Maximum Concentration of Anifrolumab in Serum After First Dose — 14.058; 28.115 mcg/mL
Phase 2 N=456 The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
Systemic Lupus Erythematosus
Primary: Cohort A: Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index-A (CLASI-A) Total Score at Week 16 — -5.0; -9.0; -10.2; -9.7 scores on a…
Phase 2 N=187 Study of Anti-Malarials in Incomplete Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: SLICC Score — 62; 56; 46; 41 participants — p=0.72
Phase 2 N=76 ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 23; 24; 2; 2 Participants
Phase 2 N=20 Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Systemic Sclerosis
Primary: Change in Modified Rodnan Skin Score (MRSS) — -10; -3.0 units on a scale
Phase 2 N=12 Topical Ruxolitinib Lichen Planus
Lichen Planus
Primary: Change in Modified Clinical Assessment Scale of Severity for Index Lesion Signs and Symptoms (mCAILS) — 11.0 score on a scale
Phase 2 N=9 Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Primary: Relapse-free Complete Clinical Response — 54 Months
Phase 1 N=35 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) — 7; 5; 5; 7 Participants
Phase 2 N=12 Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica
Necrobiosis Lipoidica
Primary: Change in Mean Necrobiosis Lipoidica (NL) Lesion Score — -2.7 score on a scale — p=0.005
Phase 2 N=99 Prospective Study of Rapamycin for the Treatment of SLE
Systemic Lupus Erythematosus (SLE)
Primary: Reduction of the Disease Activity as Measured by SLEDAI and BILAG Scores. — 10.2; 28.4 score on a scale
Phase 2 N=183 A Study to Evaluate the Efficacy and Safety of CEP-33457 in Participants With Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
Primary: Number of Participants Achieving a Combined Clinical Response Using the Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 24 — 37; 31 Participants…
Phase 2 N=289 A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Primary: Number of Participants Who Achieve SLE Responder Index (SRI) (4) Response — 29; 20; 33; 44 Number of participants — p=0.214
Phase 2 N=80 Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)
Systemic Lupus Erythematosus
Primary: Change in Vascular Function and Cardiometabolic Risk as Measured by Left CAVI at Month 3 — -0.32; 0.09 unitless